Introduction The Arg-16 β2-adrenergic receptor allele is associated with increased exacerbations in asthmatic children exposed to combination therapy with long-acting beta-agonists (LABA) and inhaled corticosteroids (ICS).1 We evaluated whether the Gly16Arg polymorphism is associated with impaired asthma control in ICS treated adult asthmatics and whether this was influenced by concomitant LABA use.
Methods In this cross-sectional study, demographics, medication and spirometry were prospectively recorded from patients attending a secondary care asthma clinic who were also genotyped and completed the Asthma Control Questionnaire (ACQ-6).
Results A total of 223 patients prescribed ICS were included in the analysis. Overall mean age was 46 years, FEV1 86%, median ICS dose 800 µg/day and 73% were prescribed LABA. There were no differences in terms of spirometry and ACQ-6 between the three genotypes (Table 1). In patients who were prescribed LABA there was no difference in ACQ-6 comparing patients with no Arg copies (n = 80, ACQ-6 1.82) versus those with one or two Arg copies (n = 83, ACQ-6 1.70). Moreover salbutamol reliever use was no different.
Conclusion Gly16Arg polymorphism was not associated with impaired asthma control in ICS treated adult asthmatics irrespective of LABA exposure.
Basu K, Palmer CN, Tavendale R, Lipworth BJ, Mukhopadhyay S. Adrenergic beta (2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol. J Allergy Clin Immunol. 2009 Dec;124(6):1188-94 e3
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.